{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:58:46Z","timestamp":1772117926139,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To retrospectively assess the development of visual acuity and the frequency and duration of relapse\u2010free periods in patients who were treated with interferon\u2010\u03b1 (IFN\u03b1) for severe uveitis due to Beh\u00e7et's disease (BD) and who completed a followup period of \u22652 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IFN alfa\u20102a was administered at an initial dosage of 6 million IU per day, then tapered to a maintenance dosage of 3 million IU twice per week, and finally discontinued, if possible. In case of a relapse, IFN treatment was repeated. Visual acuity at the end of followup was compared with visual acuity when ocular disease was in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 53 patients (96 eyes), 52 (98.1%) responded to IFN. In 47 patients (88.7%), IFN could be discontinued when the disease was in remission. Twenty of these 47 (42.6%) needed a second treatment course during a median followup of 6.0 years (range 2.0\u201312.6 years). Visual acuity improved or remained unchanged in 91 eyes (94.8%). Ocular disease was still in remission in 50% of the patients 45.9 months after cessation of the first IFN course. The relapse rate tended to be lower in women than in men. The BD activity score decreased significantly during followup, but long\u2010term remission of nonocular BD manifestations was not achieved. However, since local treatments were sufficient, no systemic treatment was administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that IFN\u03b1 induces long\u2010lasting remission in patients with severe ocular BD, resulting in a notable improvement in visual prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.27581","type":"journal-article","created":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T23:12:32Z","timestamp":1275433952000},"page":"2796-2805","source":"Crossref","is-referenced-by-count":152,"title":["Long\u2010term remission after cessation of interferon\u2010\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease"],"prefix":"10.1002","volume":"62","author":[{"given":"Christoph M. E.","family":"Deuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"M\u00f6hle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"St\u00f6biger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1970.00990040453009"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400425"},{"key":"e_1_2_7_4_2","first-page":"20","article-title":"Prognosis in Beh\u00e7et's disease","volume":"17","author":"Pivetti Pezzi P","year":"1985","journal-title":"Ann Ophthalmol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.70.8.589"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605153142005"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72840-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.09.002"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1998.00159.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.5.488"},{"key":"e_1_2_7_11_2","first-page":"1437","article-title":"Complete regression of retinal neovascularisation after therapy with interferon \u03b1 in Beh\u00e7et's disease","volume":"84","author":"Stubiger N","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.8.4.293.6453"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-19687"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.4.423"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_103"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0346-y"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101550"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080432"},{"key":"e_1_2_7_19_2","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.1.83"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-77174-3"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00407749"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.4.467"},{"key":"e_1_2_7_25_2","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades\u2010Beh\u00e7et's disease treated with interferon\u2010\u03b1\u20102a","volume":"35","author":"Krause L","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.038"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.09.010"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)31022-6"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200301000-00006"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.177"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600991927"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06651.x"},{"key":"e_1_2_7_33_2","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno S","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-006-9006-9"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27581","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:18:56Z","timestamp":1696965536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/art.27581"],"URL":"https:\/\/doi.org\/10.1002\/art.27581","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9580956.10241055","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}